Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic…
In RA, tumour necrosis factor inhibitors and methotrexate are associated with a decreased risk of all CVEs while corticosteroids and NSAIDs are associatedwith an increased risk while limited evidence suggests that systemic therapies are associatedWith a decrease in all CVE risk.
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005.
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
The results of this phase 2 trial suggest that guselkumab may be an effective therapy for plaque Psoriasis and that control of psoriasis can be achieved with specific anti-interleukin-23 therapy.
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
Despite unmet need, 15 years have passed since a topical therapy with a new mechanism of action for atopic dermatitis (AD) has been approved. Janus kinase (JAK) inhibitor treatment effect via topical…
Efficacy and safety of oral alitretinoin (9‐cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double‐blind,…
Background Patients with severe chronic hand eczema (CHE) refractory to topical corticosteroids currently have limited treatment options suited for chronic use, and few controlled clinical studies…
Daylight photodynamic therapy for actinic keratosis: an international consensus
- S. Wiegell, H. Wulf, L. Braathen
- EngineeringJournal of the European Academy of Dermatology…
- 1 June 2012
Photodynamic therapy (PDT) is an attractive therapy for non‐melanoma skin cancers including actinic keratoses (AKs) because it allows treatment of large areas; it has a high response rate and results…
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids.
A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
Tofacitinib (CP‐690,550) is a novel Janus kinase inhibitor in development as an oral formulation for the treatment of several inflammatory diseases including psoriasis.
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis
The findings of this study show that 12 weeks of once-daily treatment with 200 mg or 100 mg of oral abrocitinib resulted in significant improvement in the signs and symptoms of atopic dermatitis.